Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Thursday, November 23, 2017
 
Recommended for you
An Integrated BioSci Research On Gilead Sciences: Promising Dividends And Favorable Valuations
Seeking Alpha • Tran Biosci
Cytodyn Is Worth A Look Before Phase 3 HIV Data
Seeking Alpha • Terry Chrisomalis
Gilead Sciences: Tapping Into The Vast China Market For Growth
Seeking Alpha • Tran Biosci
Your Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage Study
Seeking Alpha • Avisol Capital Partners
Integrated BioSci Research On Atara Biotherapeutics: What's Next After CAR-T?
Seeking Alpha • Tran Biosci
How To Make Money With Gilead?
Seeking Alpha • Tran Biosci
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
Seeking Alpha • Tran Biosci
Integrated BioSci Research On Gilead Sciences: Hitting The Next Growth Spurt With CAR-TCR And TIP-VIgD
Seeking Alpha • Tran Biosci
Cramer's lightning round: Step aside, Exxon. Cimarex's quarter was 'the best'
CNBC • Elizabeth Gurdus
Close But No Cigar For Our Gilead Sciences Portfolio
Seeking Alpha • David Pinsen
 
Recommended for You
Cancer, Gilead Sciences
An Integrated BioSci Research On Gilead Sciences: Promising Dividends And Favorable Valuations
Seeking AlphaTran Biosci
Summary Gilead commenced dividend payments in 2015. Increasing the dividend is usually an indication of a firm’s improving financial strength. Dividend growth has been highly robust and likely to sustain. CAR-T to power future dividend growth while the hepatitis franchise expansion into...
Share
Gilead Sciences, Health Finance
Cytodyn Is Worth A Look Before Phase 3 HIV Data
Seeking AlphaTerry Chrisomalis
Summary Upcoming phase 3 combination data of Pro-140 with optimized background therapy could change the landscape of HIV treatment. Pro-140 has shown to be safe with fewer side effects, and has shown to suppress viral load in a lot of patients for...
Share
Gilead Sciences, Health Finance
Gilead Sciences: Tapping Into The Vast China Market For Growth
Seeking AlphaTran Biosci
Summary The upcoming launch of the hepatitis franchise in China is highly likely to ramp up sales. China has a huge population (so the overall sales will be robust). Stellar efficacy and safety of Sovaldi will enable the said drug to gain...
Share
Gilead Sciences, Health Finance
Your Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage Study
Seeking AlphaAvisol Capital Partners
Summary Gilead has adopted the right strategy in CAR-T. Egalet soars almost 40%. Aerie launches mid-stage study. This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Marketplace. Analysis of...
Share
Cancer, Epidemiology
Integrated BioSci Research On Atara Biotherapeutics: What's Next After CAR-T?
Seeking AlphaTran Biosci
Summary The approval of Yescarta proved that CAR-T (based on CD4 T cells) works. Atara uses a similar mechanism of action and targets the CAR-T (that leverages on CD8). Data for ATA-129 for EBV franchise is robust. Phase 1 results for the...
Share
Cancer, Finance
How To Make Money With Gilead?
Seeking AlphaTran Biosci
Summary Growth of the Hepatitis franchises seem to be at the end of its robust cycle, but tapping into the vast China market may spark further growth. Share price has been on a downtrend (which creates an opportunistic purchase for the intelligent...
Share
Biotechnology, Gilead Sciences
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
Seeking AlphaTran Biosci
Summary Bioscience expert, Terry Chrisomalis (“TC”), joins Integrated BioSci Investing to share his wisdom. With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences. TC recommended the stellar firm, Zogenix, that has strong catalysts brewing....
Share
Cancer, Gilead Sciences
Integrated BioSci Research On Gilead Sciences: Hitting The Next Growth Spurt With CAR-TCR And TIP-VIgD
Seeking AlphaTran Biosci
Summary Kite Pharma licensed TIP-vIgD from Alpine Immune Science for CAR-TCR innovation. Gilead recently acquired Kite for the powerful CAR-TCR platform. The recent approval of Yescarta proved that TIP-vIgD works. Growth companies grow in various spurts due to either organic developments or...
Share
Federal Reserve, Gilead Sciences
Cramer's lightning round: Step aside, Exxon. Cimarex's quarter was 'the best'
CNBCElizabeth Gurdus
Exxon Mobil Corporation: "Exxon's fine. I prefer Chevron over Exxon if you want the majors. Cimarex reported a quarter today that was the best. Club members of the ActionAlertsPlus.com club know this is my favorite. What a monster quarter." Gilead Sciences Inc.:...
Share
Finance, Gilead Sciences
Close But No Cigar For Our Gilead Sciences Portfolio
Seeking AlphaDavid Pinsen
Summary Of the hedged portfolios built with our system in late April and early May, three of the first four beat the market. This, the fifth portfolio, which was built around a Gilead Sciences position, missed slightly. We explain why, and put...
Share